DLK1 and central nervous system cancer: In agreement with our in vivo data using a mouse model that gives rise to a range of low-to-high-grade gliomas, analysis of the human TCGA LGGGBM data set [27] revealed that tumors expressing high levels of DLK1 were significantly more aggressive than those with low levels of DLK1 (Figure 7E), presumably as a result of the higher DLK1 levels reported in high-grade glioma.